A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors

Because K-Ras mutation and cyclooxygenase-2 (COX-2) overexpression are hallmarks of majority of pancreatic cancer patients, an approach to inhibit the progression and growth of pancreatic cancer using the simultaneous administration of agents that inhibit the function of both targets, should be cons...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: DING, NING, CUI, XIAO-XING, GAO, ZHI, HUANG, HUARONG, WEI, XINGCHUAN, DU, ZHIYUN, LIN, YONG, SHIH, WEICHUNG JOE, RABSON, ARNOLD B., CONNEY, ALLAN H., HU, CHUNHONG, ZHENG, XI
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2014
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4063540/
https://ncbi.nlm.nih.gov/pubmed/24647860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2014.2350
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak